Elivaldogene autotemcel (Skysona) — Coverage Criteria for Early, Active Cerebral Adrenoleukodystrophy (CALD)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria, documentation, and coding for coverage of intravenous elivaldogene autotemcel (Skysona) for boys 4–17 years with early, active CALD when no HLA‑matched donor is available; applies to Blue Cross NC members and providers.
Added applicable revenue codes 0891 and 0892 associated with HCPCS code(s) for the policy.
Added HCPCS J3387 (1 unit per treatment) to dosing reference table and removed miscellaneous drug codes C9399, J3490, J3590.
Updated indication to require that Skysona is used when there is no available HLA‑matched allo‑HSC donor.
Added distribution channel management language indicating specialty pharmacy distribution may be required.
Coverage and Medical Necessity Criteria
Initial treatment — Medical necessity criteria
Covered when ALL of the following are met
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required; Duration of approval 180 days (one treatment course per lifetime)
This policy applies to intravenous elivaldogene autotemcel (Skysona®) administered by a healthcare professional. Coverage is limited to boys aged 4–17 years with a diagnosis of active cerebral adrenoleukodystrophy (CALD) when all medical necessity criteria are met. Medical record documentation must confirm the diagnosis, demonstrate elevated very long chain fatty acids (VLCFA), and include central radiographic review of brain MRI showing a Loes score 0.5–9 (inclusive) with gadolinium enhancement. Eligible patients must also have a Neurologic Function Score (NFS) ≤ 1. Prior authorization is required and coverage is limited to a single treatment course with an approval duration of 180 days.
Skysona is indicated for use only when there is no available HLA‑matched allogeneic hematopoietic stem cell (allo‑HSC) donor and the patient has not previously undergone allogeneic HSCT or prior gene therapy. Safety laboratory thresholds (hematologic and hepatic) and infectious disease requirements must be met and documented prior to approval.
The therapy is not indicated for uses outside the specified CALD population. Requests will be considered not medically necessary when patients fail to meet any of the inclusion criteria such as being female, outside the 4–17 year age range, lacking documented active CALD, or not having the required diagnostic confirmation (elevated VLCFA and MRI with Loes 0.5–9 and gadolinium enhancement).
Coverage is also excluded for patients with any of the following: previous allogeneic hematopoietic stem cell transplantation or prior gene therapy; availability of an HLA‑matched allo‑HSC donor; hematologic compromise (ANC < 1500 cells/mm3, platelets < 100,000 cells/mm3, hemoglobin < 10 g/dL, or uncorrected bleeding disorder); hepatic compromise (AST or ALT > 2.5× ULN or total bilirubin > 3.0 mg/dL unless Gilbert's and stable); active hepatitis B; HIV infection; persistent HCV RNA positivity; or any other active infection.
Billing, Codes, and Dosing References
| J3387 | elivaldogene autotemcel (Skysona) intravenous infusion (1 unit per treatment) |
| 0891 | Special Processed Drugs - FDA Approved Cell Therapy (revenue) |
| 0892 | Special Processed Drugs - FDA Approved Gene Therapy (revenue) |
Prior Authorization, Documentation, and Distribution
Prior Authorization Required
Prior authorization is required for elivaldogene autotemcel (Skysona®). Requests should include the primary billing code HCPCS J3387 and supporting documentation to avoid delays.
- Prior authorization required — submit using HCPCS J3387
- Distribution may be restricted to specialty pharmacy when coverage is available; contact Blue Cross NC to coordinate
Distribution Channel Management
Distribution for certain gene and cellular therapies (including elivaldogene autotemcel/Skysona®) may be managed through a specialty pharmacy or other restricted distribution channel due to cost and handling requirements. Coordinate with Blue Cross NC prior to dispensing to confirm approved distribution pathway.
- Contact Blue Cross NC for coordination of specialty pharmacy distribution
- Applicable revenue codes: 0891, 0892
Documentation Requirements
Medical record documentation must be provided with the prior authorization request. Required supporting records include diagnostic test results, imaging reports, laboratory values, prior treatment history, and documentation of contraindications or exclusions.
- Diagnosis documentation confirming active cerebral adrenoleukodystrophy (CALD)
- VLCFA laboratory results showing elevated values
- Brain MRI report with central radiographic review documenting Loes score (0.5–9) and gadolinium enhancement
- Neurologic Function Score (NFS) ≤ 1
- Evidence that patient has not undergone allogeneic HSCT and lacks an HLA-matched allo-HSC donor
- Recent labs documenting ANC, platelet count, hemoglobin, AST/ALT, total bilirubin, and infection/hepatitis/HIV status
- Documentation that the patient has not had prior gene therapy and requested dose is within FDA-labeled dosing
Denial Risk Conditions
Requests may be denied if the patient does not meet the medical necessity criteria or if required documentation is missing. Common denial reasons include laboratory, imaging, or clinical findings that fall outside specified thresholds, prior allogeneic HSCT, positive HIV or active hepatitis B, evidence of significant hematologic or hepatic compromise, availability of an HLA-matched donor, prior gene therapy, or dosing outside FDA-labeled parameters.
- Patient is not male or not age 4–17; OR
- Diagnosis of active CALD not documented or confirmed; OR
- VLCFA not elevated or not provided; OR
- MRI does not show Loes score 0.5–9 and gadolinium enhancement; OR
- NFS > 1; OR
- History of allogeneic HSCT or availability of HLA-matched donor; OR
- Hematologic compromise: ANC <1500 cells/mm3, platelets <100,000/mm3, hemoglobin <10 g/dL, or uncorrected bleeding disorder; OR
- Hepatic compromise: AST or ALT >2.5× ULN, total bilirubin >3.0 mg/dL (unless Gilbert's and stable); OR
- Active hepatitis B, HIV positive, or other active infection; OR
- Positive HCV antibody with detectable HCV RNA; OR
- Prior gene therapy for any diagnosis; OR
- Requested dose outside FDA-labeled dosing; OR
- Required medical records, imaging, or lab results not submitted
Clinical Background
Cerebral adrenoleukodystrophy (CALD) is an X‑linked peroxisomal disorder characterized by progressive inflammatory demyelination of the central nervous system. Early, active CALD may present with minimal or mild clinical symptoms but is identified radiographically by gadolinium enhancement of demyelinating lesions and quantified using the Loes score (0–34); this policy permits treatment when the Loes score is between 0.5 and 9 (inclusive). The goal of elivaldogene autotemcel (Skysona) is to slow neurologic progression in boys with early, active disease who meet strict inclusion and safety criteria.
Patient selection requires assessment of gross neurologic function using the Neurologic Function Score (NFS) with eligibility limited to an NFS ≤ 1, and confirmation of peroxisomal dysfunction by elevated VLCFA. Because Skysona is an autologous CD34+ cell gene therapy intended as an alternative when no HLA‑matched donor is available, candidates must not have undergone prior allogeneic HSCT or previous gene therapy and must meet laboratory safety thresholds prior to treatment.
Key Definitions and Scales
Policy Changes
Added applicable revenue codes 0891 and 0892 associated with HCPCS code(s) for the policy (policy notification given 2/1/2026).
Added HCPCS J3387 (1 unit per treatment) to dosing reference table; removed miscellaneous/unclassified codes C9399, J3490, and J3590 (termed 12/31/2025).
Updated indication to require Skysona use when there is no available HLA‑matched allo‑HSC donor and adjusted criteria wording to align with FDA label changes; added distribution channel management language.
Original medical policy criteria issued.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.